Lamivudine/tenofovir disoproxil fumarate - Macleods Pharmaceuticals

Drug Profile

Lamivudine/tenofovir disoproxil fumarate - Macleods Pharmaceuticals

Alternative Names: Tenofovir disoproxil fumarate/lamivudine - Macleods Pharmaceuticals

Latest Information Update: 09 Jul 2015

Price : $50

At a glance

  • Originator Macleods Pharmaceuticals
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top